Since 2009, pazopanib, a potent and selective multi-targeted receptor tyrosine kinase inhibitor, is utilized for metastatic RCC and advanced soft tissue sarcomas therapy [62]. The gene discussed is NTRK1; the disease is renal cell carcinoma.